Want to see YDES full AI Analyst Report?
YDES Stock Chart & Stats
$2.17
-$0.03(-1.36%)
―
--
Day’s Range― - ―
52-Week Range$1.70 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.42K
Market Cap
$153.70M
Enterprise Value$172.49M
Total Cash (Recent Filing)$6.31K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,831,345
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-57.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtLow headline debt reduces near-term refinancing and interest-cost risk, preserving optionality for a cash-burning biotech. This durable financial flexibility supports continued R&D investment and gives management more time to advance programs before costly refinancing or dilution becomes unavoidable.
Recent Revenue GrowthReported revenue growth in 2024 versus 2023 suggests the company can expand commercial or partnered activity from a small base. Sustained top-line momentum can progressively fund operations or improve bargaining power in partnerships, a durable indicator if growth continues through execution.
Asset Base ExpansionA meaningful increase in assets in 2025 indicates investment in R&D, technology, or capacity that could underpin future value creation. If those assets are productive (IP, inventory, capex), they provide a structural foundation for scaling revenue or enabling licensing and partnerships.
Bears Say
Negative EquityMoving to negative equity is a structural balance-sheet deterioration that signals cumulative losses or aggressive financing. It heightens dilution and recapitalization risk, weakens creditor protections, and constrains strategic options; resolving negative equity typically requires material financing or restructuring.
Accelerated Cash BurnPersistent negative operating and free cash flow with accelerating burn is a durable vulnerability for a development-stage biotech. Continued outflows force reliance on external capital, exposing the company to market windows and potential dilution that can impede long-term program funding and execution.
Widening Losses & Negative Gross ProfitGross profit turning negative and materially wider losses reflect structural margin pressure or scaling costs outpacing revenue. Without sustained revenue growth or cost realignment, the company faces long-term profitability risk and limited ability to achieve self-sustaining operations.
YD Bio Limited News
YDES FAQ
What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $1.70 and its highest was $25.00 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $153.70M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
Currently, no data Available
Is YD Bio Limited overvalued?
According to Wall Street analysts YD Bio Limited’s price is currently Undervalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,831,345 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
YD Bio Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
YD Bio Limited
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Scinai Immunotherapeutics
―
Aditxt
―
SciSparc Ltd.
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
0.09% Insiders
0.06% Mutual Funds
0.04% Other Institutional Investors
99.77% Public Companies and
Individual Investors